Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement

Annals of Internal Medicine

Volumn 161, Issue 11, 2014, Pages 819-826

  LeFevre, Michael L ^a  

^a University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FOLIC ACID; PROTEIN; ANTITHROMBOCYTIC AGENT;

ARTICLE; BRAIN HEMORRHAGE; CLINICAL PRACTICE; CONGENITAL MALFORMATION; DRUG EFFICACY; FEMALE; GESTATIONAL AGE; HUMAN; INCIDENCE; LOW DRUG DOSE; MATERNAL MORBIDITY; MATERNAL MORTALITY; META ANALYSIS; PERINATAL MORTALITY; PREECLAMPSIA; PREGNANT WOMAN; PREMATURE LABOR; PREVENTIVE HEALTH SERVICE; PROGRAM EFFECTIVENESS; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; UNITED STATES; COST OF ILLNESS; MEDICAL RESEARCH; MORTALITY; PRACTICE GUIDELINE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME;

ASPIRIN; BIOMEDICAL RESEARCH; COST OF ILLNESS; FEMALE; HUMANS; PLATELET AGGREGATION INHIBITORS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; RISK ASSESSMENT;

EID: 84919499487     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-1884     Document Type: Article

References (18)

1. Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence synthesis no. 112. AHRQ publication no. 14-05207-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2014.
2. American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Washington, DC: American College of Obstetricians and Gynecologists; 2013. Accessed at www.acog.org/Resources-And-Publications/Task-Force-and -Work-Group-Reports/Hypertension-in-Pregnancy on 31 July 2014.
3. North RA, McCowan LM, Dekker GA, Poston L, Chan EH, Stewart AW, et al. Clinical risk prediction for pre-eclampsia in nulliparous women: development of model in international prospective cohort. BMJ. 2011;342:d1875. [PMID: 21474517]
4. Myatt L, Clifton RG, Roberts JM, Spong CY, Hauth JC, Varner MW, et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol. 2012;119:1234-42. [PMID: 22617589]
5. Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160:695-703. [PMID: 24711050]
6. Sibai BM, Caritis SN, Thom E, Klebanoff M, McNellis D, Rocco L, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1993;329:1213-8. [PMID: 8413387]
7. Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1998;338:701-5. [PMID: 9494145]
8. Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ. 2013;347:f6564. [PMID: 24201165]
9. U.S. Preventive Services Task Force. Aspirin prophylaxis in pregnancy. In: Guide to Clinical Preventive Services. 2nd ed. Washington, DC: U.S. Department of Health and Human Services; 1996.
10. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007;(2):CD004659. [PMID: 17443552]
11. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369:1791-8. [PMID: 17512048]
12. Jensen MS, Rebordosa C, Thulstrup AM, Toft G, Sorensen HT, Bonde JP, et al. Maternal use of acetaminophen, ibuprofen, and acetylsalicylic acid during pregnancy and risk of cryptorchidism. Epidemiology. 2010;21:779-85. [PMID: 20805751]
13. Keim SA, Klebanoff MA. Aspirin use and miscarriage risk. Epidemiology. 2006;17:435-9. [PMID: 16755260]
14. Low dose aspirin in pregnancy and early childhood development: follow up of the Collaborative Low dose Aspirin Study in Pregnancy. CLASP Collaborative Group. Br J Obstet Gynaecol. 1995;102:861-8. [PMID: 8534620]
15. World Health Organization. WHO Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia. Geneva: World Health Organization; 2011. Accessed at http://whqlibdoc.who.int/publications/2011/9789241548335-eng.pdf on 31 July 2014.
16. Redman CW. Hypertension in pregnancy: the NICE guidelines. Heart. 2011;97:1967-9. [PMID: 21990386]
17. Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council for High Blood Pressure Research. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:1545-88. [PMID: 24503673]
18. American Academy of Family Physicians. Recommendations for Clinical Preventive Services. Leawood, KS: American Academy of Family Physicians; 2014. Accessed at www.aafp.org/patient-care/clinical-recommendations/cps.html on 31 July 2014.